The independent source for health policy research, polling, and news.
2,561 - 2,580 of 3,967 Results
Interest in medical schools is high in Puerto Rico, but many students look to the U.S. mainland for residencies because of higher pay and the commonwealth's declining economy. The migration of young talent is both a symptom and an exacerbation of the island’s medical woes.
A program designed to address the shortage of doctors in rural and poor urban areas could be in peril unless Congress acts.
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
A critical shortage of home health care workers across the U.S. is denying care for senior citizens and people with disabilities.
The Trump administration has pledged to create jobs and shrink health care spending — almost a contradiction in a country where health care is a roaring engine of the economy.
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
Doctors are beginning to pay attention to injuries, such as brain damage or kidney failure, that can afflict people who survive an overdose.
New research shows that physicians getting H-1B visas account for just over 1 percent of all doctors, but some areas are much more likely to be seeking their services.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Kaiser Health News gives readers a chance to respond, react and comment on our stories.
The nonprofit Leapfrog Group shows nearly half of California hospitals got a grade of C, D or F in patient safety measures — an increase from two years ago.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The powerful chairman of the Senate Judiciary Committee wants the Centers for Medicare and Medicaid Services to explain $125 million in overcharges by insurers.
Even though the GOP health plan is stalled by intraparty negotiations, some big insurance changes are still in the works.
In a region where bears outnumber people, a small medical facility sets a modern example for rural hospitals on life support.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
Amplifying the "patient voice," those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
There are many ways beyond legislative repeal for the Trump administration and congressional Republicans to unravel the Affordable Care Act.
© 2026 KFF